Our Pipeline
Explore
A tetravalent, bispecific dual-antagonist antibody engineered by the fusion of TALTZ® (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF.
An anti-IL-7Rα inhibitor that has the potential to impact diseases driven by IL-7 and TSLP biological pathways.
A fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent (e.g., RAGE) inflammation.
“Zura Bio is focused on the development of therapies in challenging immunological conditions by deeply interrogating the therapeutic mechanism of action and pairing that with those patients with greatest need. This represents a unique opportunity for us to bring life-changing therapies to patients.”
Michael Howell, PhD
Chief Scientific Officer & Head of Translational Medicine